The trial was terminated due to an out-licensing agreement after the new sponsor did not wish to continue the trial

The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections

Inclusion Criteria:

• Male and female patients 18 to 85 years of age with suspected and/or bacteriologically documented complicated UTI judges by the investigator to be serious (required patient to be hospitalized for treatment with intravenous antibiotics)

Exclusion Criteria:

• Urine Gram stain that demonstrated that a Gram-positive organism was present, or if urine culture results were available, demonstrated Gram- positive organisms were present at ≥10E5 CFU/mL
• Urine culture result available at enrollment and demonstrating more than 2 different species of microorganisms regardless of the colony count
• Urine culture result available demonstrating fungal UTI with colony count >10E3 CFU/mL
• Patient had received prior antibiotics within 72 hours before the initiation of study therapy
• Patients with estimated glomerular filtration rate < 30mL/min calculated based in study qualified formula

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

A blinded evaluator will perform the safety and efficacy assessments